Secondary analysis of a TB preventive treatment trial in people with HIV in 3 African countries: 13.0% (196/1502) had QFT-Plus conversion by month 12, similar with 3HP and 6H; 19.0% reverted, and baseline positivity was linked to higher TB risk.
Secondary analysisn = 1,502
Saavedra-Cervera et al. Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries